China
Africa
Explore chapters and articles related to this topic
Anesthesia and Analgesia for Donkeys, Mules and Foals
Published in Michele Barletta, Jane Quandt, Rachel Reed, Equine Anesthesia and Pain Management, 2023
Tomas Williams, Michele Barletta
Alpha-2 agonists should be used with caution in very young patients. They cause cardiovascular depression by increasing afterload and decreasing heart rate, which can be detrimental in neonates. Bradycardia, respiratory depression and severe ataxia can be noticed. In older foals xylazine 0.5–1 mg/kg can be used if necessary.
Beta and Alpha Particle Autoradiography
Published in Michael Ljungberg, Handbook of Nuclear Medicine and Molecular Imaging for Physicists, 2022
Anders Örbom, Brian W. Miller, Tom Bäck
The Alpha Camera imaging has been used for imaging of several α-emitting radionuclides, for example, 211At, 213Bi, 225Ac, 227Th and 223Ra, and mostly in experimental studies of targeted alpha therapy.
Pharmacology of the Lower Urinary Tract
Published in Karl H. Pang, Nadir I. Osman, James W.F. Catto, Christopher R. Chapple, Basic Urological Sciences, 2021
Pedro Abreu-Mendes, João Silva, Francisco Cruz
Adverse effects:Dizziness, rhinitis, headache, asthenia, postural hypotension are AEs related to the alpha-1B AR. More common in non-selective alpha-blockers.Silodosin (Alpha-A1 selective) − better CV profile but higher rate of ejaculatory dysfunction.Tamsulosin (and possibly silodosin also) is associated with a high risk of floppy iris syndrome (Alpha-1A).
The efficacy of neurofeedback for alcohol use disorders – a systematic review
Published in The World Journal of Biological Psychiatry, 2023
NF therapy is now being used to treat a variety of mental diseases, with promising results. In recent years, the influence of EEG frequency biofeedback as a therapy technique for psychiatric problems has been extensively studied. NF improves self-efficacy and has a positive impact on the brain’s self-control capabilities. Furthermore, increased alpha activity is thought to assist the patient in remaining calm and better coping with stress. Participants are likely to acquire increased self-confidence and minimise emotional stress, feelings of inadequacy, insecurity and fear as a result of increasing control over physiological processes (Dalkner et al. 2017). Vernon et al. (2003) conducted a study in which volunteers participated in a series of NF sessions. They found that individuals who received NF improved their recall from 70.6 to 81.6%, whereas those who did not get NF only improved their recall from 72.5 to 75.1%. We reviewed the existing literature and included studies that reported the effectiveness of NF interventions on AUD. The purpose of this study is to explore if NF training may help patients with AUDs avoid relapse, reduce anxiety and despair, and minimise alcohol cravings and consumption. A total of 20 studies, mostly RCTs, using a number of NF methods for patients with AUDs were included. The non-pharmacological interventions include EEG NF training (11 studies), rtfMRI-NF (3 studies), tDCS (2 studies), TMS (2 studies), DBS (1 study) and TBS (1 study).
Emerging treatment options for prostate cancer
Published in Expert Review of Anticancer Therapy, 2023
Mohammad Atiq, Elias Chandran, Fatima Karzai, Ravi A. Madan, Jeanny B. Aragon-Ching
Alpha particles are attractive as these deliver high energy with fewer particle tracks to effect cell kill, have a short depth of penetration, and have shorter half-lives, potentially limiting toxicity to normal tissues. Additionally, from a practical perspective, the easier production of alpha particles lends for wider dissemination and use in the clinic [47]. The only alpha emitter approved thus far in prostate cancer is radium 223 dichloride. One alpha emitter being evaluated is actinium-225 (225Ac). A phase I study combining this with a PSMA-localizing antibody, J591, was recently presented by Tagawa et al. (NCT03276572) [48,49]. Thirty-two patients with mCRPC who progressed on at least 1 ARPI and chemotherapy were enrolled in the study. Interestingly, prior treatment with radium 223 and lutetium was allowed, and PSMA PET positivity was not required for enrollment. There was only one patient with dose-limiting toxicity (DLT) at all the planned dose levels: grade 4 anemia and thrombocytopenia. Grade 3 or higher AEs were hematologic. Lower grade AEs included fatigue, pain flare, nausea, and xerostomia (which occurred in 8 patients – 5 previously treated with lutetium – and was limited to grade 1). Clinical data presented included 22 out of 32 patients having any decline in PSA and 12 out of 32 patients experiencing ≥50% PSA reduction (PSA50 response).
Advances in luminescence-based technologies for drug discovery
Published in Expert Opinion on Drug Discovery, 2023
Bolormaa Baljinnyam, Michael Ronzetti, Anton Simeonov
To generate a recognition pair that can be applied to a screening campaign, the surfaces of the beads are conjugated to the assay-specific molecules such as streptavidin, biotin, analyte-specific antibodies, protein A, or other widely used protein affinity tags. These conjugations then allow highly specific and tight binding of the beads to the respective target molecules. The flexibility in bead conjugation, very high assay signal, low background, convenient homogenous assay format, and excellent stability of the reagents make the Alpha technology well suited for high-throughput screenings during early drug discovery campaigns. AlphaScreen and AlphaLISA have been successfully applied to target GPCR family members, proteases, kinases, and other enzymes involved in posttranslational and epigenetic modifications, and interactions between biomolecules (reviewed in [67]). Due to its high adaptability to different types of biomolecules, Alpha technologies has been applied for biotherapeutic development as well [68–70].